Stock listing

ASX:OSX Osteopore Ltd. Share Price

Follow Osteopore Ltd. into a list and get an email when it puts out news.

Share price · ASX:OSX

$0.0030 AUD 0.0000 (0.0%)

Close on Nov 19, 2026

Past year -66.7% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
$0.0030 – $0.0030 AUDNov 19, 2026
Market cap
$2.08M AUDAt the close on Nov 19, 2026 · price × 693.6M shares outstanding
52-week range
$0.0030 – $0.0290 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$2,240 AUDMedian day 55,242 shares · 21 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
Osteopore Ltd. logo

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · ASX:OSX · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00304,786
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00309,334
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.0030103,000
$0.0030-0.0005-14.3%$0.0030$0.0030$0.0030534
$0.00350.00000.0%$0.0035$0.0035$0.00350
$0.00350.00000.0%$0.0035$0.0035$0.00350
$0.0035+0.0005+16.7%$0.0035$0.0035$0.003560,000
$0.0030-0.0010-25.0%$0.0030$0.0030$0.003055,242
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.00400.00000.0%$0.0040$0.0040$0.00404,238,000
$0.00400.00000.0%$0.0030$0.0040$0.0030222,587
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.00400.00000.0%$0.0040$0.0040$0.00403,500
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.00400.00000.0%$0.0040$0.0040$0.0040188,650
$0.0040+0.0010+33.3%$0.0040$0.0040$0.004091,500
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.0030130,000
$0.00300.00000.0%$0.0040$0.0040$0.0030323,379
$0.0030-0.0010-25.0%$0.0030$0.0030$0.0030107,307
$0.00400.00000.0%$0.0040$0.0040$0.004088,845
$0.0040+0.0005+14.3%$0.0030$0.0040$0.00301,210,063
$0.00350.00000.0%$0.0035$0.0035$0.0035120,667
$0.00350.00000.0%$0.0035$0.0035$0.00359
$0.0035-0.0005-12.5%$0.0035$0.0035$0.0035596,667
$0.0040+0.0010+33.3%$0.0030$0.0040$0.0030837,792
$0.0030-0.0010-25.0%$0.0040$0.0040$0.0030501,334
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.0040+0.0010+33.3%$0.0040$0.0040$0.0040837,531
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.0030-0.0015-33.3%$0.0040$0.0040$0.00301,675,892
$0.00450.00000.0%$0.0045$0.0045$0.00450
$0.0045+0.0005+12.5%$0.0040$0.0045$0.0040690,000
$0.00400.00000.0%$0.0040$0.0040$0.0040125,000
$0.00400.00000.0%$0.0035$0.0040$0.00354,522,302
$0.0040+0.0010+33.3%$0.0040$0.0040$0.00402,235
$0.00300.00000.0%$0.0030$0.0030$0.0030137,644
$0.0030-0.0010-25.0%$0.0030$0.0030$0.0030427
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.00400.00000.0%$0.0040$0.0040$0.0040800,000
$0.00400.00000.0%$0.0040$0.0040$0.0040130,000
$0.00400.00000.0%$0.0040$0.0040$0.00401,175,000
$0.00400.00000.0%$0.0040$0.0040$0.00306,285,054
$0.00400.00000.0%$0.0040$0.0040$0.0040800,000
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.0040-0.0010-20.0%$0.0040$0.0040$0.00402,955,948
$0.00500.00000.0%$0.0050$0.0050$0.00500
$0.0050+0.0010+25.0%$0.0050$0.0050$0.005050,000
$0.0040-0.0010-20.0%$0.0040$0.0040$0.00406,468,248
$0.00500.00000.0%$0.0050$0.0050$0.005050,000
$0.00500.00000.0%$0.0050$0.0050$0.0050400
$0.0050+0.0005+11.1%$0.0050$0.0050$0.0050378,221
$0.00450.00000.0%$0.0045$0.0045$0.00450
$0.00450.00000.0%$0.0045$0.0045$0.00450
$0.0045+0.0005+12.5%$0.0040$0.0050$0.0040126,898
$0.00400.00000.0%$0.0040$0.0040$0.00400
$0.0040-0.0005-11.1%$0.0045$0.0045$0.004066,105
$0.00450.00000.0%$0.0045$0.0045$0.004525,000
$0.00450.00000.0%$0.0045$0.0045$0.0045417,249
$0.0045-0.0005-10.0%$0.0045$0.0045$0.004550,000
$0.00500.00000.0%$0.0050$0.0050$0.00501,150,000

Splits

1 split · ASX:OSX · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
Ticker
ASX:OSX
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Osteopore Ltd. news

Osteopore Ltd. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
26 in the last 12 months · 118 in all · newest Nov 1, 2026 · oldest 2019
Decks
11 decks · latest March 2025

Valuation

EV/sales 0.3× against a median of 0.5×: 4th lowest of 8 Medical devices & supplies companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 19, 2026

Enterprise value
$900,557 AUD
P/E
Loss
EV/sales
0.3×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
53.0%
Operating margin
−87.4%
Net margin
−121.8%
Debt to equity
Negative equity
Beta
No index for this market yet

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Osteopore Ltd. · ASX:OSXUS$1.38MUS$596,079n/a0.3×n/an/a−121.8%n/an/a
Fuse Medical, Inc. · OTC:FZMDUS$2.03MUS$4.31M14.8×0.5×7.8×0.3×1.5%0.4×0.54
Nuwellis, Inc. · NASDAQ:NUWEUS$1.84M−US$6.31Mn/a−0.7×n/a0.2×−152.8%0.0×2.26
Vivos Therapeutics, Inc. · NASDAQ:VVOSUS$1.83MUS$2.11Mn/a0.1×n/a0.8×−107.1%0.2×1.41
Autonomix Medical, Inc. · NASDAQ:AMIXUS$1.82M−US$5.87Mn/an/an/a0.3×n/a0.0×1.79
Adagio Medical Holdings, Inc · NASDAQ:ADGMUS$1.72MUS$636,0102.1×n/an/a0.1×n/a0.1×0.69
Escalon Medical Corp. · OTC:ESMCUS$1.71M−US$1.96M0.4×−0.1×n/a0.3×32.8%0.0×-0.06
Therma Bright Inc. · TSXV:THRMUS$1.66MUS$1.64Mn/a17.3×n/an/an/an/a-0.15
Nexalin Technology, Inc. · NASDAQ:NXLUS$1.45MUS$1.88Mn/a6.8×n/a5.5×n/a4.7×0.52
Zero Candida Technologies Inc. · TSXV:ZCTUS$1.43M−US$59,297n/an/an/a2.2×n/a0.0×-0.17
SpectraCure AB · OMXSTO:SPECUS$978,306US$1.10Mn/a32.1×n/a0.1×n/a0.1×n/a
Median of the othersUS$1.71MUS$869,8022.1×0.5×7.8×0.3×−52.8%0.1×0.54

Team and board

Officers

OfficerRole
Lim YujingChief Technology Officer
Harry MillerCompany Secretary
Ammar HassanbhaiSenior Manager, Quality Assurance
James Lim Jae HoonCountry Manager, Korea, Global Business Director, Aesthetic Rhinoplasty
Mark LeongExecutive Chairman
Voon Shu NingGroup Financial Controller

Board

DirectorRole
Mark LeongExecutive Chairman
Michael KeenanNon-Executive Director
Teoh Swee HinNon-Executive Director

Events

QuarterResultsShare move
Q2 2025Aug 29, 20250.0%
Quarter to Mar 31, 2025Apr 7, 2025−20.0%
Q4 2022Feb 28, 2023 · After close0.0%
Q2 2022Aug 31, 2022−5.0%
Q4 2021Mar 31, 20220.0%
Q2 2021Aug 31, 2021+5.9%
Q4 2020Feb 26, 2021−2.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2025)Investor deck29 slidesMarch 2025
Investor Presentation (August 2023)Investor deck39 slidesAug 1, 2023
Investor Presentation (February 2023)Investor deck28 slidesFeb 20, 2023
Investor Presentation (August 2022)Investor deck22 slidesAug 10, 2022
Investor Presentation (November 2021)Investor deck17 slidesNov 22, 2021
Investor Presentation (June 2021)Investor deck17 slidesJun 10, 2021
Investor Presentation (March 2021)Investor deck28 slidesMar 22, 2021
Investor Presentation (November 2020)Investor deck13 slidesNov 24, 2020
Investor Presentation (August 2020)Investor deck36 slidesAug 21, 2020
Investor Presentation (February 2020)Investor deck31 slidesFeb 7, 2020
All 11 decks
DeckKindSlidesDate
Investor Presentation (October 2019)Investor deck30 slidesOct 22, 2019

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.06M2.81M2.22M1.69M1.11M1.50M414.1K934.9K610.6K204.8K
Cost of revenue1.44M445.5K581.5K419.1K301.4K549.3K123.5K216.5K143.2K82.8K
Gross profit1.62M2.37M1.64M1.27M811.6K955.3K290.6K718.4K467.4K122.0K
Research and development1.45M1.14M1.57M1.43M
Selling, general and administrative3.74M2.21M2.03M4.52M4.20M3.28M1.53M1.45M824.1K1.03M
Operating income-2.67M-2.82M-4.93M-4.22M-3.89M-2.64M-2.37M-901.9K-528.9K-1.06M
Depreciation and amortization748.7K531.1K464.4K218.2K225.5K165.9K72.6K77.1K72.9K48.3K
EBITDA-1.92M-2.29M-4.46M-4.00M-3.67M-2.48M-2.29M-824.9K-456.0K-1.01M
Interest expense280.0K426.0K15.0K20.4K16.3K17.6K15.6K000
Income before tax-3.72M-3.33M-4.83M-4.20M-3.62M-1.95M-2.38M-870.2K-447.0K-972.8K
Income tax1.67K19.2K43.5K20.4K307.8K742.1K18.1K3-1
Net income-3.72M-3.35M-4.87M-4.22M-3.62M-1.95M-2.38M-870.2K-447.0K-972.8K
Earnings per share, basic-0.02-0.04-0.08-0.51-0.46-0.27-1.24-0.02-0.01-0.03

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents627.0K638.5K1.16M2.16M4.93M9.03M3.29M4.99M33.8K28.9K
Short-term investments5.92K5.75K5.56K13.1K201.6K16.4K15.8K9.94K9.91K
Receivables1.05M1.07M643.0K866.3K400.7K361.4K542.2K223.9K106.9K575.3K
Inventory362.9K379.5K279.0K279.2K201.6K151.4K23.5K28.1K23.7K45.1K
Current assets2.59M2.35M2.28M3.15M5.42M9.74M3.97M5.24M164.3K649.4K
Property, plant and equipment183.4K322.5K285.1K467.2K587.8K506.3K309.9K167.4K177.7K209.4K
Total assets2.77M3.13M3.34M3.62M6.01M10.2M4.28M5.40M349.6K858.8K
Accounts payable1.62M647.0K785.9K1.37M450.8K325.7K211.4K166.7K44.5K13.9K
Current liabilities3.05M2.72M2.91M1.48M564.5K1.25M1.29M1.17M2.18M2.22M
Long-term debt1.41M
Total debt198.8K1.33M1.09M74.2K148.8K454.0K596.6K665.8K510.2K209.3K
Total liabilities4.50M2.83M2.91M1.51M633.4K1.25M1.32M1.17M2.18M2.22M
Shareholders' equity-1.73M306.2K432.6K2.11M5.37M9.00M2.97M4.23M-1.84M-1.36M
Shares outstanding186.1M78.3M57.8M8.24M7.82M7.11M1.92M38.2M38.2M38.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-2.56M-3.09M-3.74M-4.00M-3.81M-1.76M-1.75M-334.1K11.2K-184.3K
Capital spending-10.8K-14.6K-7.37K-64.0K-194.6K-381.0K-78.3K-66.5K-49.2K-73.6K
Free cash flow-2.57M-3.10M-3.74M-4.06M-4.00M-2.14M-1.83M-400.6K-38.0K-257.9K
Cash from investing-10.8K-14.6K-7.37K-64.0K-194.6K-381.0K407.3K1.47M-49.2K-73.6K
Cash from financing2.67M2.63M3.58M896.3K-485.9K7.84M4.64M-602.1K35.6K263.2K
Dividends paid-48.7K
Share buybacks0-109.6K-169.8K-54.1K0-563.4K-241.7K
Change in cash-5.78K-476.3K-219.4K-3.20M-4.50M5.73M3.29M505.1K4.86K5.27K

Open Financials

Filings

FilingDateTypeFiled with
OSX focuses on Ortho line in Singapore via direct sellingNov 1, 2026Operations updateASX
Activities Report September 2026 and Appendix 4COct 30, 2026Quarterly reportASX
Resignation and appointment of Company SecretaryOct 2, 2026Management or board changeASX
OSX secures market access to Thailand orthopaedic marketSep 8, 2026Operations updateASX
Half Yearly Report and AccountsAug 31, 2026Interim reportASX
OSX strikes orthopaedic deal for 5 Middle East countriesAug 5, 2026Acquisition or disposalASX
Details of Auditor Appointment/ResignationAug 3, 2026Other filingsASX
OSX completes first Hainan custom orthopaedic implantAug 2, 2026Operations updateASX
Activities Report June 2026 and Appendix 4CJul 30, 2026Quarterly reportASX
OSX secures Hainan FDA approval for orthopaedic devicesMay 25, 2026Operations updateASX
All 115 filings
FilingDateTypeFiled with
Activities Report March 2026 and Appendix 4CApr 29, 2026Quarterly reportASX
Further Drawdown of T2 of the Redeemable Convertible NotesMar 26, 2026FinancingASX
Clarification - agreement for injectable regen bone fillerMar 12, 2026Operations updateASX
OSX signs agreement for injectable regenerative bone fillerMar 11, 2026Operations updateASX
OSX secures distribution for autologous dentin bone graftMar 2, 2026Operations updateASX
Appendix 4E Preliminary Final ReportFeb 27, 2026Annual reportASX
Drawdown of Tranche 2 of the Redeemable Convertible NotesFeb 16, 2026FinancingASX
OSX secures Latin America deal for craniofacial distributionFeb 12, 2026Operations updateASX
Further Drawdown of T1 of the Redeemable Convertible NotesFeb 6, 2026FinancingASX
Activities Report December 2025 and Appendix 4CJan 29, 2026Quarterly reportASX
Clarification - agreement for orthopaedic products in HKJan 22, 2026Other filingsASX
OSX strikes agreement for orthopaedic products in Hong KongJan 21, 2026Operations updateASX
Clarification - OSX partner Chinese dental & maxillofacialJan 16, 2026Operations updateASX
OSX partners up for Chinese dental & maxillofacial marketJan 15, 2026Acquisition or disposalASX
OSX partners DKSH for dental products in MalaysiaNov 24, 2025Operations updateASX
Activities Report September 2025 and Appendix 4COct 30, 2025Quarterly reportASX
OSX collaborates with TTSH to develop novel implant for AVNSep 8, 2025Operations updateASX
OSX Invests AUD 0.5m in Cellular Regenerative MedicineAug 31, 2025Operations updateASX
Half Yearly Report and AccountsAug 29, 2025Interim reportASX
OSX ortho product successful in Vietnam hospital tender bidsAug 3, 2025Operations updateASX
Activities Report June 2025 and Appendix 4CJul 30, 2025Quarterly reportASX
Business progress update, Zimmer Biomet sales units grows 3xJul 28, 2025Operations updateASX
Osteopore gains access to SwitzerlandJul 13, 2025Operations updateASX
Activities Report March 2025 and Appendix 4CApr 28, 2025Quarterly reportASX
Osteopore secures EU market approvals for custom implantsApr 8, 2025Operations updateASX
Reinstatement to QuotationApr 7, 2025Trading halt or suspensionASX
Suspension from QuotationMar 31, 2025Trading halt or suspensionASX
Convertible Note ProspectusMar 28, 2025FinancingASX
Drawdown of Tranche 1 of the Redeemable Convertible NotesFeb 14, 2025FinancingASX
Activities Report December 2024 and Appendix 4CJan 30, 2025Quarterly reportASX
OSX enters agreement to issue redeemable convertible notesDec 24, 2024FinancingASX
OSX partners scientists to drive regeneration innovationNov 3, 2024Operations updateASX
Activities Report September 2024 and Appendix 4COct 30, 2024Quarterly reportASX
Osteopore to raise A$20m via redeemable convertible noteSep 26, 2024FinancingASX
OSX and University of Chile complete bone implant studiesAug 21, 2024Operations updateASX
Activities Update Qtr Ending June 2024 and Appendix 4CJul 30, 2024Quarterly reportASX
Osteopore strikes Exclusive Distribution with Zimmer BiometJul 15, 2024Other filingsASX
A$18.7m Osteopore, NDCS and A*STAR project hits milestonesJun 5, 2024Operations updateASX
OSX and SingHealth partner on Global Centre of ExcellenceMay 13, 2024Operations updateASX
Osteopore successfully raises A$2.9m from Entitlement OfferMay 7, 2024FinancingASX
Activities Update Qtr Ending March 2024 and Appendix 4CApr 29, 2024Quarterly reportASX
Response to ASX Price and Volume QueryApr 23, 2024Explanation requestASX
Trading HaltApr 23, 2024Trading halt or suspensionASX
Pause in TradingApr 23, 2024Trading halt or suspensionASX
Reinstatement to Official QuotationApr 16, 2024Trading halt or suspensionASX
Response to ASX Query LetterApr 15, 2024Explanation requestASX
Osteopore extends Bridging Loan maturity dateApr 10, 2024FinancingASX
Replacement Prospectus for Renounceable Rights IssueApr 4, 2024Offer documentASX
Update to Replacement Prospectus for Entitlement OfferApr 3, 2024Offer documentASX
Osteopore secures Singapore and Vietnam market approvalsMar 26, 2024Operations updateASX
Prospectus for Renounceable Rights IssueMar 12, 2024Offer documentASX
OSX Entitlement Offer to support growthMar 12, 2024FinancingASX
Activities Update Qtr Ending December 2023 and Appendix 4CJan 30, 2024Quarterly reportASX
Notice of General MeetingJan 23, 2024Meeting noticeASX
Osteopore signs Bridging Loan agreementDec 28, 2023FinancingASX
Activities Update Qtr Ending September 2023 and Appendix 4COct 30, 2023Quarterly reportASX
MOU with Temasek-linked Innoventures - Orthopaedics in ChinaSep 11, 2023Other filingsASX
Activities Update Qtr Ending June 2023 and Appendix 4CJul 30, 2023Quarterly reportASX
OSX receives A$10m commitment for commercialisation in ChinaJul 24, 2023Other filingsASX
Osteopore strengthens Board & Management by key appointmentsJul 17, 2023Other filingsASX
Strategic Partnership for Clinical R&D in China worth $4MJun 7, 2023Other filingsASX
Largest South African Medical Insurer provides cover for OSXMay 15, 2023Other filingsASX
Activities Update Qtr Ending March 2023 and Appendix 4CApr 27, 2023Quarterly reportASX
OSX Successfully transitions to EU Medical Device RegulationApr 26, 2023Other filingsASX
Reinstatement of Security Class to QuotationApr 25, 2023Other filingsASX
Security Class Suspension from QuotationApr 24, 2023Trading halt or suspensionASX
Non-Renounceable Entitlement Offer - ResultsApr 24, 2023FinancingASX
OSX Strengthens Presence in the Eastern Region of the USAApr 10, 2023Other filingsASX
OSX Completes Acquisition to Accelerate Revenue GrowthMar 30, 2023Acquisition or disposalASX
Non-Renounceable Entitlement Offer ProspectusMar 12, 2023FinancingASX
Non-Renounceable Entitlement OfferMar 12, 2023FinancingASX
Activities Update Qtr Ending December 2022 and Appendix 4CJan 30, 2023Quarterly reportASX
Integration of Acquired Business for Higher Sales & MarginJan 22, 2023Acquisition or disposalASX
Firm Commitments and Non-Binding Proposed AcquisitionDec 21, 2022Acquisition or disposalASX
Suspension from Official QuotationDec 20, 2022Trading halt or suspensionASX
Increased presence and commercial opportunities across SEADec 7, 2022Other filingsASX
Activities Update Qtr Ending September 2022 and Appendix 4COct 30, 2022Quarterly reportASX
Osteopore Moves Closer to China Market EntryAug 22, 2022Other filingsASX
Activities Update Qtr Ending June 2022 and Appendix 4CJul 25, 2022Quarterly reportASX
OSX Enter Oral & Maxillofacial Market in Australia & NZMay 10, 2022Other filingsASX
Activities Update Qtr Ending March 2022 and Appendix 4CApr 28, 2022Quarterly reportASX
SHG: & CSIRO AI Tool to Optimise Cranial Implant ProceduresMar 13, 2022Other filingsASX
Activities Update Qtr Ending December 2021 and Appendix 4CJan 27, 2022Quarterly reportASX
Osteopore secures A$19m clinical-industrial partnershipDec 13, 2021Other filingsASX
Activities Update Qtr Ending September 2021 and Appendix 4COct 29, 2021Quarterly reportASX
SHG: CSIRO Collaboration for AI-based ToolOct 18, 2021Other filingsASX
Activities Update Qtr Ending June 2021 and Appendix 4CJul 30, 2021Quarterly reportASX
Activities Update Qtr Ending March 2021 and Appendix 4CApr 30, 2021Quarterly reportASX
Agreement with Terumo Blood and Cell TechnologiesJan 31, 2021Other filingsASX
Activities Update Qtr Ending December 2020 and Appendix 4CJan 29, 2021Quarterly reportASX
OSX Signs Australian & New Zealand Distribution AgreementOct 30, 2020Other filingsASX
Activities Update Qtr Ending September 2020 and Appendix 4COct 29, 2020Quarterly reportASX
Investor PresentationAug 21, 2020Other filingsASX
Osteopore Receives Binding Commitments for $8.5m PlacementAug 20, 2020FinancingASX
Activities Update Quarter Ending June 2020 and Appendix 4CJul 31, 2020Quarterly reportASX
Development of New 3D Printed Bone ImplantJul 22, 2020Other filingsASX
Clarification on Initial US Distribution AgreementJul 2, 2020Other filingsASX
Osteopore Signs Initial U.S. Distribution AgreementJul 1, 2020Other filingsASX
Activities Update Quarter Ending March 2020 and Appendix 4CApr 30, 2020Quarterly reportASX
Osteopore Receives Australian TGA ApprovalApr 19, 2020Other filingsASX
Pause In TradingApr 16, 2020Trading halt or suspensionASX
Company UpdateApr 8, 2020Other filingsASX
Company Update and Appendix 4CJan 30, 2020Quarterly reportASX
Former President and CEO of Cochlear Joins as Board AdvisorDec 3, 2019Other filingsASX
OSX Executes Memorandum of Co-operation in Hainan ProvinceNov 18, 2019Other filingsASX

Open Filings

Cap table

Built by 6ix from Osteopore Ltd.’s releases

Common shares
693,592,914
Fully diluted
693,592,914

Fully diluted

LineShares
Common shares693,592,914

Share count over time

CountShares
Nov 22, 2026693,592,914

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ammar HassanbhaiSenior Manager, Quality Assurance · Since at least Nov 4, 2026
Harry MillerCompany Secretary · Since at least Oct 2, 2026
Jack RosagroUntil Oct 2, 2026 · Past
James Lim Jae HoonCountry Manager, Korea, Global Business Director, Aesthetic Rhinoplasty · Since at least Nov 4, 2026
Lim YujingChief Technology Officer · Since at least May 12, 2025
Mark LeongExecutive Chairman · Since at least Nov 5, 2026
Michael KeenanNon-Executive Director · Since at least Nov 5, 2026
Teoh Swee HinNon-Executive Director · Since at least Nov 5, 2026
Voon Shu NingGroup Financial Controller · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Osteopore Ltd.